Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -8 of 8
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/29/2008
 
First Published:
5/23/2003
1.
Phase I/II Study of BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
BIOCRYST-1777BC-103
NCT00061880
2.
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
Any age
Pharmaceutical / Industry
BCX1777-Bi-04-106
NCT00289562
Last Modified:
6/2/2008
 
First Published:
6/23/2004
3.
Phase II Study of Forodesine in Patients With Recurrent or Refractory Advanced T-Cell Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
Any age
Pharmaceutical / Industry
BIOCRYST-BCX1777-T-04-201
NCT00095381, UCLA-0404017-01
4.
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
BCX1777-Bo-05-204
NCT00289549
5.
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
BCX1777-Tio-05-202
NCT00419081
Last Modified:
7/12/2007
 
First Published:
7/26/2003
6.
Phase I Study of BCX-1777 in Patients With Refractory Hematologic Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
16 and over
Pharmaceutical / Industry
BIOCRYST-1777BC-102
NCT00066235
Last Modified:
1/29/2008
 
First Published:
11/20/2003
7.
Phase I Study of BCX-1777 in Patients With Refractory T-Cell or Non-T-Cell Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
BIOCRYST-1777BC-101
CCF-5909, NCT00073944
Last Modified:
7/10/2007
 
First Published:
11/15/2004
8.
Phase I Study of Forodesine (BCX-1777) in Patients With Refractory Stage IIA-IVB Cutaneous T-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
BIOCRYST-BCX1777-C-04-105
NCT00098332
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute